Betta Pharmaceuticals announced that the BPI-572,300 capsule clinical trial declared by the company in January 2026 was approved and is currently in the dose climbing and dose backfilling stage; recently, the wholly-owned subsidiary Jingyao Biology declared clinical trial applications for this capsule combined with chemotherapy, PD-1 monoclonal antibodies plus platinum-containing chemotherapy, FAK inhibitors, EGFR antibodies, etc. were accepted by the State Drug Administration. The acceptance numbers are CXHL2601291, CXHL2601292, and CXHL2601293.

Betta Pharmaceuticals announced that the BPI-572,300 capsule clinical trial declared by the company in January 2026 was approved and is currently in the dose climbing and dose backfilling stage; recently, the wholly-owned subsidiary Jingyao Biology declared clinical trial applications for this capsule combined with chemotherapy, PD-1 monoclonal antibodies plus platinum-containing chemotherapy, FAK inhibitors, EGFR antibodies, etc. were accepted by the State Drug Administration. The acceptance numbers are CXHL2601291, CXHL2601292, and CXHL2601293.